High-rolling investors have positioned themselves bullish on Fortinet FTNT, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.

Shiba Inu's burn rate spiked over 2,260% in 24 hours, with 13.6 million SHIB destroyed in a single transaction. Traders cite Shibarium growth and bullish technicals as key drivers, projecting a potential 122% upside.

TORONTO, May 12, 2025 ( GLOBE NEWSWIRE ) -- Revive Therapeutics Ltd. ( "Revive" or the "Company" ) ( OTCQB: RVVTF ) ( CSE: RVV ) ( FRANKFURT:31R ) , a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, ...

Amazon's new robots boost sorting, reduce labor costs, and could add $10B in profits with 10% fulfillment savings. Analyst sees long-term gains from robotics, drone delivery, and AI as Amazon scales automation across operations.

The deal allows American Bitcoin direct access to capital markets via Gryphon's existing Nasdaq listing infrastructure. The merged company intends to focus on efficient mining operations and building a large-scale Bitcoin treasury reserve.

New York, New York, 12th May ...

A thawing in the U.S./China trading relationship is excellent news for a company like GE HealthCare Technologies ( NASDAQ: GEHC ) . It's a large exporter to China ( a market management sees as having excellent long-term potential ) and uses Chinese-sourced components in its products.

Key takeaways: Possible de-risking ahead of the May 13 CPI print could be playing a role in today's BTC price correction. Bitcoin market structure and qualitative fundamentals remain bullish, suggesting today's correction could be short-lived.Bitcoin ( BTC ) price briefly stumbled on May 12, ...

KeyBanc upgraded Federal Signal to Overweight with a $110 target, impressed by its strategic focus and competitive efforts. The analyst anticipates solid organic and inorganic growth leading to strong financials and a widening competitive advantage.

Teverelix addresses a $2 billion U.S. market with no approved drug for AUR recurrence, per analyst Jason Kolbert. SKNJCT-003 Phase 2 trial shows over 60% clearance rate in BCC with no serious adverse events reported.